Top 10 drugs with the fastest sales growth in 2015

Source: pharmaceutical economic news 2016-05-25 the top 50 drugs with the fastest growth in global sales in 2015 increased by US $41 billion compared with last year Gilead's hepatitis C drug, harvoni alone, has generated $11.7 billion in growth, or 29% of the total There are 8 drugs with sales growth of more than US $1 billion, 3 of which are hepatitis C drugs, all of which were listed in 2014 The top 10 drugs with the fastest growth totaled $23 billion, or 56% of the total At the same time, abbvie's Humira and Pfizer's prevnar ranked in the top 10 of the top 10 fastest-growing drugs in 2015 and the top 10 best-selling drugs in 2015, and the Revlimid of celgene failed to enter the top 10 sales growth Among the top 20 drugs on the sales growth list, it is worth noting that some of them are newly marketed In addition to hepatitis C drugs, GlaxoSmithKline's 2014 launch of the HIV drug trimeq saw a $1 billion increase Opdivo, a PD-1 inhibitor launched by Bristol Myers Squibb at the end of 2014, generated $942 million in sales in 2015 (only $6 million in 2004) Pfizer's new breast cancer drug launched in early 2015 had a growth of $723 million, ranking 13th on the list In the top 50 list of sales growth, Roche has five drugs with a total growth of $1.9 billion; Johnson & Johnson has four drugs with a total growth of $2 billion Three companies on the list are Bristol Myers Squibb (growth: US $3.4 billion, the same below), Aberdeen (US $3.3 billion), Novo Nordisk (US $1.8 billion), GlaxoSmithKline (US $1.8 billion), new base medicine (US $1.5 billion) and Baijian (US $1.3 billion) Gilead has only two drugs on the list, but has the highest growth of $12.4 billion Among these drugs, hepatitis C drugs grew the most, with 14.7 billion US dollars and tumor drugs increased by 6.5 billion US dollars With the increasing pressure of payment in the United States, diabetes drugs still have a growth of $2.8 billion, while anticoagulants, immunotherapeutics and HIV drugs each have a growth of $2.1 billion.